Abstract
Personalized medicine systematically uses all available information about a patient, including his/her molecular make-up, in order to optimize preventive, diagnostic, and/or therapeutic measures. In gastroenterology, it is mainly applied for managing inflammatory bowel diseases (therapeutic approach, drug toxicity), gastrointestinal malignancies (development of biomarkers of early recognition, therapy optimization), viral hepatitis (markers of response to therapy, optimization of therapy), H. pylori associated diseases (virulency, tendency to develop certain complications, response to therapy), and many other diseases. Despite the anticipated financial and ethical obstacles, personalized medicine offers the possibility of more precise diagnostics, more accurate therapy, and better prevention, which will in turn result in better long-term treatment outcomes.
Professor Davor Štimac, M.D., Ph.D., Head of KBC Rijeka, Division of Gastroenterology, Department of Internal medicine, University Hospital Rijeka, Rijeka, Croatia.
Neven Franjić, M.D., Ph.D., Division of Gastroenterology, Department of Internal medicine, University Hospital Rijeka, Rijeka, Croatia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Notes
- 1.
Guttmacher and Collins (2002) Zavod za javno zdravstvo “dr. Andrija Štampar”, Personalizirana medicina. Available at: http://www.stampar.hr/Default.aspx?art=2229&sec=16.
- 2.
Hamburg and Collins (2010).
- 3.
Issa (2007).
- 4.
Gill et al. (2006).
- 5.
Patel and Babyatsky (2008).
- 6.
- 7.
Patel and Babyatsky (2008).
- 8.
Weinshilboum and Sladek (1980).
- 9.
Coenen et al. (2014).
- 10.
Panaccione and Ghosh (2010).
- 11.
Markowitz and Bertagnolli (2009).
- 12.
Patel and Babyatsky (2008).
- 13.
- 14.
Ramchandani et al. (2007).
- 15.
Yen and McLeod (2007).
- 16.
Saito and Camilleri (2006).
- 17.
Ge et al. (2009).
- 18.
Morrow et al. (2009).
- 19.
European Association for the Study of the Liver (2014).
- 20.
Miki et al. (2012).
- 21.
- 22.
Malfertheiner et al. (2012).
- 23.
- 24.
- 25.
D’Haens et al. (2008).
- 26.
Dignass et al. (2010).
- 27.
Bouvier et al. (2010).
- 28.
Schmalfuss and Kolominsky-Rabas (2013).
- 29.
Guttmacher and Collins (2002); Zavod za javno zdravstvo “dr. Andrija Štampar”, Personalizirana medicina. Available at: http://www.stampar.hr/Default.aspx?art=2229&sec=16.
References
Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–962
Bouvier AM, Sant M, Verdecchia A et al (2010) What reasons lie behind long-term survival differences for gastric cancer within Europe? Eur J Cancer 46(6):1086–1092
Chao C (2012) Overview of personalized medicine in GI cancers. J Gastrointest Surg 16(9):1641–1644
Chong E, Ensom MH (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23(4):460–471
Coenen M, van Marrewijk C, Derijks L et al (2014) Personalized thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients. Results from a randomized trial in the Netherlands. J Crohns Colitis 8(Suppl 1):S4
D’Haens G, Baert F, van Assche G et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371(9613):660–667
Dignass A, van Assche G, Lindsay JO et al (2010) The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4(1):28–62
Dossumbekova A, Prinz C, Rad R et al (2006) Helicobacter pylori outer membrane proteins and gastric inflammation. Gut 55:1360–1361
European Association for the Study of the Liver (2014) EASL practice guidelines: management of hepatitis C virus infection. J Hepatol 60(2):392–420
Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399–401
Gill SR, Pop M, De Boy RT et al (2006) Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359
Guttmacher AE, Collins FS (2002) Genomic medicine – a primer. N Engl J Med 347:1512–1520
Hagymasi K, Müllner K, Herszényi L et al (2011) Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 12(6):873–888
Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363:301–304
Hunfeld NG, Mathot RA, Touw DJ et al (2008) Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 65(5):752–760
Issa A (2007) Personalized medicine and the practice of medicine in the 21st century. Mcgill J Med 10(1):53–57
Lynch HT, Lynch JF, Lanspa SJ (2010) Familial pancreatic cancer. Cancers 2(4):1861–1883
Malfertheiner P, Megraud F, O’Morain CA et al (2012) Management of Helicobacter pylori infection – the Maastricht IV/Florence Concensus Report. Gut 61:646–664
Markowitz SD, Bertagnolli MM (2009) Molceular basis of colorectal cancer. N Engl J Med 361:2449–2460
Mendoza JL, Abreu MT (2009) Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 33(Suppl 3):S158–S173
Miki D, Ochi H, Hayes CN et al (2012) Hepatocelullar carcinoma: towards personalized medicine. Cancer Sci 103(5):846–850
Morrow MP, Pankhong P, Laddy DJ et al (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113(23):5868–5877
Ozawa S, Soyama A, Sawada J et al (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19:83–95
Panaccione R, Ghosh S (2010) Optimal use of biologics in the management of Crohn’s disease. Therap Adv Gastroenterol 3(3):179–189
Patel KP, Babyatsky MW (2008) Medical education: a key partner in realizing personalized medicine in gastroenterology. Gastroenterology 134:656–661
Ramchandani R, Wang Y, Booth BP et al (2007) The role of SN-38 exposure UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan activity. J Clin Pharmacol 47:78–86
Saito YA, Camilleri M (2006) Clinical application of pharmacogenetics in gastrointestinal diseases. Expert Opin Pharmacother 7:1857–1869
Schmalfuss F, Kolominsky-Rabas PL (2013) Personalized medicine in screening for malignant disease: a review of methods and applications. Biomark Insights 8:9–14
Somma V, Ababneh H, Ababneh A et al (2013) The novel Crohn’s disease marker anti-GP2 antibody is associated with ileocolonic location of disease. Gastroenterol Res Pract 2013:683824. doi:10.1155/2013/683824
Tešija Kuna A (2013) Serological markers of inflammatory bowel disease. Biochem Med (Zagreb) 23(1):28–42
Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5):651–662
Wen S, Velin D, Pan-Hammarström Q et al (2007) Expression of Helicobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun 75:5118–5126
Yen JL, McLeod HL (2007) Should DPD analysis be required prior to prescribing fluorpyrimidines? Eur J Cancer 43:1011–1016
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Štimac, D., Franjić, N. (2016). Personalized Medicine in Gastroenterology. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G. (eds) Personalized Medicine. Europeanization and Globalization, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-319-39349-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-39349-0_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-39347-6
Online ISBN: 978-3-319-39349-0
eBook Packages: Law and CriminologyLaw and Criminology (R0)